Dongming Cai

Dr. Dongming Cai

Department of Neurology, Icahn School of Medicine at Mount Sinai, 1468 Madison Avenue, New York, NY 10029, USA
orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2002 in Neuron
Verified
Journal Article
Closed access
JQJin Qiu
Jin Qiu
DCDongming Cai
Dongming Cai
HDHaining Dai
Haining Dai
MMMarietta McAtee
Marietta McAtee
PHPaul N. Hoffman
Paul N. Hoffman
MFMarie T. Filbin
Marie T. Filbin

1 January 1999 in Neuron
Verified
Journal Article
Closed access
DCDongming Cai
Dongming Cai
YSYingjing Shen
Yingjing Shen
MBMaria Elena de Bellard
Maria Elena de Bellard
STSong Tang
Song Tang
MFMarie T Filbin
Marie T Filbin

8 January 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
RNRyan A. Neff
Ryan A. Neff
MWMinghui Wang
Minghui Wang
SVSezen Vatansever
Sezen Vatansever
LGLei Guo
Lei Guo
CMChen Ming
Chen Ming
BZBin Zhang
Bin Zhang
Alzheimer’s disease (AD), the most common form of dementia, is recognized as a heterogeneous disease with diverse pathophysiologic mechanisms. In this study, we interrogate the molecular heterogeneity of AD by analyzing 1543 transcriptomes across five brain regions in two AD cohorts using an integrative network approach. We identify three major molecular subtypes of AD corresponding to different combinations of multiple dysregulated pathways, such as susceptibility to tau-mediated neurodegeneration, amyloid-β neuroinflammation, synaptic signaling, immune activity, mitochondria organization, and myelination. Multiscale network analysis reveals subtype-specific drivers such as GABRB2, LRP10, MSN, PLP1, and ATP6V1A. We further demonstrate that variations between existing AD mouse models recapitulate a certain degree of subtype heterogeneity, which may partially explain why a vast majority of drugs that succeeded in specific mouse models do not align with generalized human trials across all AD subtypes. Therefore, subtyping patients with AD is a critical step toward precision medicine for this devastating disease.

1 August 2002 in Neuron
Verified
Journal Article
Closed access
DCDongming Cai
Dongming Cai
KDKangwen Deng
Kangwen Deng
WMWilfredo Mellado
Wilfredo Mellado
JLJunghee Lee
Junghee Lee
RRRajiv R Ratan
Rajiv R Ratan
MFMarie T Filbin
Marie T Filbin

12 December 2018 in Molecular Neurodegeneration
Verified
Journal Article
Open access
PDF file
JCJiqing Cao
Jiqing Cao
JHJianwei Hou
Jianwei Hou
JPJing Ping
Jing Ping
DCDongming Cai
Dongming Cai
Alzheimer’s Disease (AD), the most prevalent neurodegenerative disease of aging, affects one in eight older Americans. Nearly all drug treatments tested for AD today have failed to show any efficacy. There is a great need for therapies to prevent and/or slow the progression of AD. The major challenge in AD drug development is lack of clarity about the mechanisms underlying AD pathogenesis and pathophysiology. Several studies support the notion that AD is a multifactorial disease. While there is abundant evidence that amyloid plays a role in AD pathogenesis, other mechanisms have been implicated in AD such as tangle formation and spread, dysregulated protein degradation pathways, neuroinflammation, and loss of support by neurotrophic factors. Therefore, current paradigms of AD drug design have been shifted from single target approach (primarily amyloid-centric) to developing drugs targeted at multiple disease aspects, and from treating AD at later stages of disease progression to focusing on preventive strategies at early stages of disease development. Here, we summarize current strategies and new trends of AD drug development, including pre-clinical and clinical trials that target different aspects of disease (mechanism-based versus non-mechanism based, e.g. symptomatic treatments, lifestyle modifications and risk factor management).

11 March 2024 in Molecular Neurodegeneration
Verified
Journal Article
Open access
PDF file
MZMichael Z. Zhong
Michael Z. Zhong
TPThomas Peng
Thomas Peng
MDMariana Lemos Duarte
Mariana Lemos Duarte
MWMinghui Wang
Minghui Wang
DCDongming Cai
Dongming Cai
Alzheimer’s disease (AD) is the most common neurodegenerative disease in the United States (US). Animal models, specifically mouse models have been developed to better elucidate disease mechanisms and test therapeutic strategies for AD. A large portion of effort in the field was focused on developing transgenic (Tg) mouse models through over-expression of genetic mutations associated with familial AD (FAD) patients. Newer generations of mouse models through knock-in (KI)/knock-out (KO) or CRISPR gene editing technologies, have been developed for both familial and sporadic AD risk genes with the hope to more accurately model proteinopathies without over-expression of human AD genes in mouse brains. In this review, we summarized the phenotypes of a few commonly used as well as newly developed mouse models in translational research laboratories including the presence or absence of key pathological features of AD such as amyloid and tau pathology, synaptic and neuronal degeneration as well as cognitive and behavior deficits. In addition, advantages and limitations of these AD mouse models have been elaborated along with discussions of any sex-specific features. More importantly, the omics data from available AD mouse models have been analyzed to categorize molecular signatures of each model reminiscent of human AD brain changes, with the hope to guide future selection of most suitable models for specific research questions to be addressed in the AD field.